In adult cancers, acquired oncogenic alterations and age-related immune decline contribute to altered expression of NF-κB, IL-6 (a downstream target of NF-κB), and STAT3 signaling, altering immune recognition and cellular senescence [370,371]. This evidence concerns the gene IL6 and cancer.